The new findings add to wider concerns about the South African variant, which recently showed significant resistance to the vaccine developed by AstraZeneca and Oxford University in a small-scale trial.
Those results spurred South Africa’s government to scrap the vaccine in favor of the single-dose shot produced by Johnson & Johnson.